New research published by Marshall University and promoted by Science Daily, reveals that patients who recover from invasive pneumococcal pneumonia may suffer shorter longevity.
New research has been published in Vaccine on pneumococcal disease in hospitals (Canada)
We detail below some organisations interested in adult immunisation. We also provide some links to information about vaccine preventable diseases impacting on older people. We will update this list every 3 months. [last updated January 2017]
British man who contracted pneumococcal virus recalls his story as new film highlights the dangers of pneumococcal infection.
Following Hillary Clinton’s diagnosis of pneumonia, global public attention in the disease has increased dramatically. But what is pneumonia, and how can it be prevented?
A systematic review of the relevant literature in English on the cost-effectiveness of immunisation for adults aged 50 years or over in all EU Member States was performed for the SAATI report (see below). Cost-effectiveness studies were found for 13 EU Member States (the UK, Germany, the Netherlands, Sweden, Belgium, France, Italy, Spain, Poland, Denmark, Finland, Slovakia and Czech Republic) and for 4 of the seven key vaccine preventable diseases examined in this report: herpes zoster, seasonal influenza, IPD and pneumococcal pneumonia.
Pneumonia is a major cause of death and hospitalisation, but is not required by law to be reported to government authorities in most EU countries.
‘Is pneumonia contagious? And how long does the flu last?’
‘The estimated vaccine effectiveness was 57%. This means that about 57% of hospitalisations due to influenza-associated pneumonia could be prevented through vaccination’.
‘I just couldn’t believe I had pneumonia… I thought it was only something old people got’